BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

NiKem Research s.r.l. Receives Qualification for Bioanalysis of Clinical Samples


4/14/2010 2:44:02 PM

Baranzate, Italy, April, 13th 2010 / b3c newswire / - NiKem Research is pleased to announce that it has received on March 18th 2010, from the regional authority ASL Milano 1 of Regione Lombardia (Prot. N. 24588), the qualification to perform Pharmacokinetic, Metabolism and Bioequivalence analyses for clinical trials on healthy volunteers, according to Italian D.M. 19 March 1998. AIFA (Italian Medicines Agency) is now recording NiKem Research qualification.

This represents a further and exciting development of NiKem’s established preclinical GLP bioanalysis services. NiKem Research has, for many years, provided high quality cost-effective bioanalytical support both for its in vitro ADME(T) and in vivo PK services associated to various drug discovery programs and as a standalone capability. We are now able to offer our bioanalysis as a GLP service to not only support our clients preclinical PK and toxicology, but also our clients clinical studies. Our new capability allows us to analyse biological samples from clinical studies to supply certified bioanalyses for:

• Method development and validation by HPLC-UV or UPLC/MS/MS;

• New Chemical Entity (NCE) Phase I studies on healthy volunteers;

• Clinical bioequivalence studies.

Giuseppe Giardina, CEO & Managing Director of NiKem, said “This new set of services is another important step in NiKem’s continuing expansion of its high quality and cost effective platform to support progression of our clients’ drug discovery programmes into the clinic”.

About NiKem Research - www.nikemresearch.com

Based on decades of drug discovery experience, NiKem Research offers a full range of Drug Discovery services to the pharmaceutical industry. In addition to its medicinal chemistry expertise in hit validation and multiparametric lead optimization, NiKem Research offers synthetic chemistry and parallel synthesis capabilities, computational and analytical chemistry services. Furthermore, ADMET profiling, biochemical pharmacology screening and in vivo PK services can be provided either as an integrated Drug Discovery platform or as individual service modules. NiKem Research usually operates as a fee-for-service partner although other business models can be used to ensure maximum value to our clients. All tangible and intangible assets generated during a collaboration are assigned to the client. www.nikemresearch.com


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES